Ms. Anu Acharya, CEO of Mapmygenome, said “Our genetics-based lung cancer and nicotine dependence test is the culmination of requests from several key members of the medical community. This is our way of saying No to tobacco and Yes to oxygen.”
The test uses single nucleotide polymorphism genotyping of proven markers associated with lung cancer in order to study inherited and acquired changes in DNA that contribute to the disease risk. The nicotine dependence markers allow users to understand their nicotine dependence pattern and formulate better smoking cessation plans.
Mapmygenome is India’s pioneering Genomics Company with a vision to provide "Better Health for Indians using technology."
They have a range of personal genomics tests that include Genomepatri™
Mapmygenome also offers brain wellness solutions in India under the portfolio Mapmybrain™. This includes MyCalmBeat™ to reduce stress, to improve lung function, and to optimize heartbeat. Another innovative product in this range is WebNeuro™ test to screen cognitive strengths and efficiency.
Mapmygenome also offers Spoligo TB kit for detecting and typing TB. They also have PCR & sequencing molecular diagnostic tests for β-Thalassemia, Hepatitis B, Hepatitis C, and HIV. More kits and tests will be launched soon other diseases.
Their team at Hyderabad comprises biotechnologists, statisticians, geneticists, bioinformaticians, medical writers, and genetic counselors. Their advisory panel has expert scientists and doctors. In order to enhance this innovative brand and to provide value-added services to customers, their highly skilled research team works on cutting-edge technologies in various domains.
For more information, visit: www.mapmygenome.in.